Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1
[Paper-level Aggregated] PMCID: PMC7293710
Evidence Type(s): Oncogenic
Summary: Mutation: G12V | Summary: The KRASG12V mutation contributes to tumor development and progression, as it is involved in the context of cancer cell viability and response to therapy.
Gene→Variant (gene-first): KRAS(3845):G12V
Genes: KRAS(3845)
Variants: G12V
Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1
[Paper-level Aggregated] PMCID: PMC7293710
Evidence Type(s): Predictive
Summary: Mutation: G12V | Summary: The KRASG12V mutation is associated with increased sensitivity to the antiproliferation therapy of metformin in colorectal cancer cell lines, indicating a predictive relationship with treatment response.
Evidence Type: Predictive
Gene→Variant (gene-first): KRAS(3845):G12V
Genes: KRAS(3845)
Variants: G12V
Next, we determined whether metformin had superior antitumor activity in KRAS-mutated CRC cell lines to those with KRAS wild type through a cell-viability test. As shown in SI Appendix, Fig. S2A, metformin inhibited the
[Paragraph-level] PMCID: PMC7293710 Section: RESULTS PassageIndex: 7
Evidence Type(s): Predictive, Oncogenic
Summary: Evidence Type: Predictive | Mutation: G12V | Summary: The KRASG12V mutation is associated with increased sensitivity to the antiproliferation therapy of metformin in colorectal cancer cell lines, indicating a predictive relationship with treatment response. Evidence Type: Oncogenic | Mutation: G12V | Summary: The KRASG12V mutation contributes to tumor development and progression, as it is involved in the context of cancer cell viability and response to therapy.
Gene→Variant (gene-first): 3845:G12V
Genes: 3845
Variants: G12V
Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1
[Paper-level Aggregated] PMCID: PMC7293710
Evidence Type(s): Oncogenic, Predictive
Justification: Oncogenic: The KRASG12V mutation is associated with increased sensitivity to metformin, indicating its role in promoting tumor growth and response to therapy in colorectal cancer cell lines. Predictive: The presence of the KRASG12V mutation predicts the response of CRC cells to metformin treatment, as evidenced by the differential effects observed in KRAS-mutated versus KRAS wild type cells.
Gene→Variant (gene-first): KRAS(3845):G12V
Genes: KRAS(3845)
Variants: G12V
Next, we determined whether metformin had superior antitumor activity in KRAS-mutated CRC cell lines to those with KRAS wild type through a cell-viability test. As shown in SI Appendix, Fig. S2A, metformin inhibited the
[Paragraph-level] PMCID: PMC7293710 Section: RESULTS PassageIndex: 7
Evidence Type(s): Predictive, Oncogenic
Justification: Predictive: The passage discusses how the KRASG12V mutation correlates with increased sensitivity to the antiproliferation therapy of metformin, indicating a predictive relationship between the variant and treatment response. Oncogenic: The KRASG12V mutation is implicated in tumor development as it is mentioned in the context of its effect on cell viability and sensitivity to therapy in colorectal cancer cell lines.
Gene→Variant (gene-first): 3845:G12V
Genes: 3845
Variants: G12V
Next, we determined whether metformin had superior antitumor activity in KRAS-mutated CRC cell lines to those with KRAS wild type through a cell-viability test. As shown in SI Appendix, Fig. S2A, metformin inhibited the
[Paragraph-level] PMCID: PMC7293710 Section: RESULTS PassageIndex: 7
Evidence Type(s): Predictive, Oncogenic
Justification: Predictive: The passage discusses how the KRASG12V mutation correlates with increased sensitivity to the antiproliferation therapy of metformin, indicating a predictive relationship between the variant and treatment response. Oncogenic: The KRASG12V mutation is implicated in tumor development as it is mentioned in the context of its effect on cell viability and sensitivity to therapy in colorectal cancer cell lines.
Gene→Variant (gene-first): 3845:G12V
Genes: 3845
Variants: G12V